astragaloside a has been researched along with Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, K; Liu, M; Ni, S; Sun, L; Wang, J; Xu, X; Zhao, X | 1 |
| Du, M; Gao, Y; He, Y; Liu, H; Wang, H; Wang, Z; Wu, X | 1 |
2 other study(ies) available for astragaloside a and Multiple Sclerosis
| Article | Year |
|---|---|
Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy.
Topics: Animals; Brain; Chitosan; Disease Models, Animal; Mice; Multiple Sclerosis | 2023 |
Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.
Topics: Animals; Antioxidants; Apoptosis Regulatory Proteins; CD11b Antigen; Cell Line; Cytokines; Demyelinating Diseases; Disease Models, Animal; Disease Progression; Drugs, Chinese Herbal; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Inflammation; Mice; Multiple Sclerosis; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Nuclear Receptor Subfamily 1, Group F, Member 3; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Saponins; T-Box Domain Proteins; Th1 Cells; Th17 Cells; Triterpenes | 2013 |